GENIXCURE Inc. is building its future growth on next-generation AAV vector platforms, aiming to secure global competitiveness through the integration of AI-driven, innovative vector development.

Our proprietary CARE™ platform, powered by InsightMiner™, is a core technology designed to overcome the limitations of conventional AAV in terms of cell tropism, safety, and productivity. This breakthrough opens new possibilities for developing gene therapies targeting neurodegenerative diseases.

By expanding R&D capabilities through collaboration with domestic and global partners, we strive to deliver safe and effective therapeutic options to patients.

At GENIXCURE, our top priority is to bring new hope to patients suffering from intractable diseases.

Through our proprietary machine learning platform InsightMiner™ powered by the CARE™ system, we develop high-efficiency next-generation AAV vectors with enhanced target specificity, immune evasion, and reduced toxicity.